Quarterly report [Sections 13 or 15(d)]

Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement (Details Narrative)

v3.26.3
Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Jul. 30, 2026
Jul. 28, 2026
Sep. 30, 2026
Dec. 31, 2025
Asset Acquisition [Line Items]        
Preferred stock, par value     $ 0.0001 $ 0.0001
Common stock, par value     $ 0.0001 $ 0.0001
Options assumed in the Vidya Acquisition     1,047,524  
Gross proceeds from issuance of private placement $ 200,000      
Securities Purchase Agreement [Member]        
Asset Acquisition [Line Items]        
Gross proceeds from issuance of private placement   $ 200,000    
Series A Preferred Stock [Member]        
Asset Acquisition [Line Items]        
Stock issued during period shares new issues     306,574.202 0
Share issued price per shares [1]   $ 1.22119    
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]        
Asset Acquisition [Line Items]        
Stock issued during period shares new issues   163,774.679    
Common shares issuable upon conversion of preferred stock 163,774,679      
Share issued price per shares   $ 1,221.19    
Conversion price per share   $ 1.22119    
Vidya Therapeutics, Inc. [Member]        
Asset Acquisition [Line Items]        
Total consideration [2]   $ 175,000    
Transaction costs   $ 2,700    
Vidya Therapeutics, Inc. [Member] | Series A Non-Voting Convertible Preferred Stock [Member]        
Asset Acquisition [Line Items]        
Shares issued on consideration   142,254.972    
Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member]        
Asset Acquisition [Line Items]        
Shares issued on consideration   142,254,972    
Preferred stock, par value   $ 0.0001    
Conversion of shares   1,000    
Common stock, par value   $ 0.0001    
Total consideration   $ 175,000    
Description for equity interest   As a result of the acquisition and related private placement transaction, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.4% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 52.6% of our common stock, in each case, calculated on a fully diluted basis (assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values.    
Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member] | Merger Agreement [Member]        
Asset Acquisition [Line Items]        
Options assumed in the Vidya Acquisition   1,047,524    
Total consideration   $ 175,400    
Transaction costs   2,700    
Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member] | Merger Agreement [Member] | Advisor [Member]        
Asset Acquisition [Line Items]        
Acquisition costs   $ 700    
Stock issued during period shares new issues   544.551    
[1] The fair market valuation of the Series A Preferred Stock was determined based on the contractual conversion price per share, on an as-converted basis (1,000 shares of common stock for 1 share of Series A Preferred Stock).
[2] Represents the Vidya Acquisition research and development projects which were in process, but not yet completed, and which we may advance following the Vidya Acquisition, including the development of VT-7208. The fair value of IPR&D projects acquired in an asset acquisition with no alternative future use are charged to expense on the acquisition date. Substantially all of the fair value of the gross assets acquired was concentrated in the acquired IPR&D, a single identifiable asset, and the transaction therefore passed the screen test under ASC 805. Accordingly, the acquired set of assets did not meet the definition of a business. Additionally, the acquired assets did not include the outputs or meaningful processes necessary to be considered a business under ASC 805. The IPR&D was recorded at the fair value of the consideration given.